Opportunity ID: 296478

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-DK-17-509
Funding Opportunity Title: Limited Competition for the Continuation of the Drug Induced Liver Injury Network (DILIN) Clinical Centers (U01)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Food and Nutrition
Health
Category Explanation:
Expected Number of Awards: 6
Assistance Listings: 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Aug 14, 2017
Last Updated Date:
Original Closing Date for Applications: Dec 05, 2017
Current Closing Date for Applications: Dec 05, 2017
Archive Date: Jan 10, 2018
Estimated Total Program Funding: $2,140,000
Award Ceiling: $250,000
Award Floor:

Eligibility

Eligible Applicants: Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. See FOA for full eligibility details.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this Funding Opportunity Announcement is for a limited competition for clinical centers for the continuation of the Drug-induced Liver Injury Network (DILIN). The DILIN Clinical Centers are the components of the Network to identify, enroll and clinically characterize patients eligible for the DILIN. The companion RFA (RFA-DK-17-510) seeks to continue the Data Coordinating Center for DILIN Drug-induced liver injury (DILI) is one of the more challenging forms of liver disease; both in diagnosis and management. Several hundred drugs, nutritional supplements and herbal medications have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease. Over the last 14 years, the DILIN Network throughout its publications (http://www.dilin.org/publications/) have become the major source of information and progress in understanding and possibly decreasing the burden of drug-induced liver injury for clinicians, hepatologists, researchers, and the public at large in the US and Worldwide.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-17-509.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email: FBOWebmaster@OD.NIH.GOV

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-D Use for due dates on or after May 25, 2016 PKG00234293 Nov 05, 2017 Dec 05, 2017 View

Package 1

Mandatory forms

296478 RR_SF424_2_0-2.0.pdf

296478 PHS398_CoverPageSupplement_3_0-3.0.pdf

296478 RR_OtherProjectInfo_1_3-1.3.pdf

296478 PerformanceSite_2_0-2.0.pdf

296478 RR_KeyPersonExpanded_2_0-2.0.pdf

296478 PHS398_ResearchPlan_3_0-3.0.pdf

Optional forms

296478 RR_Budget_1_3-1.3.pdf

296478 RR_SubawardBudget30_1_3-1.3.pdf

296478 PHS398_ModularBudget_1_2-1.2.pdf

296478 PHS_Inclusion_Enrollment_Report-1.0.pdf

296478 PHS_AssignmentRequestForm-1.0.pdf

2025-07-09T15:42:19-05:00

Share This Post, Choose Your Platform!

About the Author: